Follow the evidence
Scientific sources checked October 21, 2026. Earlier research and provider sources retain their dated histories below. Scientific articles identify the original reports and labeling examined, with access limits stated in each article. Provider pages document advertised offers.
- FDA — Zepbound approval and dual receptor activityHistorical approval announcement; mechanism context
- MedlinePlus — tirzepatide injectionFederal patient drug information
- Aronne et al. — SURMOUNT-5, NEJM 2025 (PubMed abstract)Randomized trial; abstract reviewed, not full-text appraisal
- Frías et al. — SURPASS-2, NEJM 2021 (PubMed abstract)Randomized diabetes trial; abstract reviewed
- CoreAge Rx — official treatment pagesProvider offer
- CoreAge Rx — tirzepatide offerProvider offer
- CoreAge Rx Help Center — Pricing & PlansProvider billing terms
- SuperHealthy Rx — current GLP-1 offerProvider offer
- Likeness Rx — GLP-1 plans and billingProvider offer
- Ro Body — membership and medication costsProvider offer
- WeightWatchers — Med+ membership and medicationProvider offer
- LillyDirect — pharmacy access and independent care optionsManufacturer access program
- FDA — concerns with unapproved GLP-1 drugsRegulator guidance
- FDA — compounding questions and answersRegulator guidance
- FDA — dosing errors with compounded injectable semaglutideSafety alert, July 2024
- NIDDK — prescription medications for overweight and obesityFederal patient education
- Clinical Trial ParticipationPrimary health resource; checked October 5, 2026
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity - PubMedPrimary source; original trial abstracts used for trial summaries
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes - PubMedPrimary source; original trial abstracts used for trial summaries
- Prescription Medications to Treat Overweight & Obesity - NIDDKPrimary health resource; checked October 5, 2026
- Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension - PubMedPrimary health resource; checked October 5, 2026
- GLP-1 agonists: MedlinePlus Medical EncyclopediaFederal patient information; checked October 5, 2026
- FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight LossPrimary health resource; checked October 5, 2026
- Understanding Unapproved Use of Approved Drugs "Off Label"Federal patient information; checked October 5, 2026
- Telehealth for Weight Loss, Hair Loss, Skin & More | Mochi HealthProvider public offer; checked October 5, 2026
- Henry | Personalized Weight Loss, Hormone & Sexual Health CareProvider public offer; checked October 5, 2026
- Henry | Personalized Weight Loss, Hormone & Sexual Health CareProvider public offer; checked October 5, 2026
- Weight Loss Care for Women, Built to Last | HersProvider public offer; checked October 5, 2026
- FAQs | HersProvider public offer; checked October 5, 2026
- Frequently Asked Questions (FAQs) | Form HealthProvider public offer; checked October 5, 2026
- What is the cost of medication? - Form Health Patient Support CenterProvider public offer; checked October 5, 2026
- Ondra Health: Pricing and pharmacy availabilityProvider public information; checked October 15, 2026
- Ondra Health: Compounded semaglutide plansProvider public information; checked October 15, 2026
- Ondra Health: Compounded tirzepatide plansProvider public information; checked October 15, 2026
- Ondra Health: Refund and cancellation policyProvider public information; checked October 15, 2026
- Ondra Health: Terms of serviceProvider public information; checked October 15, 2026
- Fitish RX: Compounded semaglutide with B6Provider public information; checked October 15, 2026
- Fitish RX: Compounded tirzepatide injectionProvider public information; checked October 15, 2026
- Fitish RX: Oral tirzepatide tabletsProvider public information; checked October 15, 2026
- Fitish RX: Return and exchange policyProvider public information; checked October 15, 2026
- Fitish RX: State service descriptionsProvider public information; checked October 15, 2026
- Fitish RX: Terms and conditionsProvider public information; checked October 15, 2026
- Fitish RX: Care and program FAQProvider public information; checked October 15, 2026
- Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss.Full primary post hoc analysis main text and main Table 1 reviewed; supplementary file and original trial protocols not independently reviewed. · Checked 2026-10-21
- Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT-1 to -4 trials.Full primary post hoc report, Methods, Results, main Table 1 and Discussion/funding reviewed; supplementary tables and source-trial protocols not separately reviewed. · Checked 2026-10-21
- DailyMed: WEGOVY semaglutide current prescribing informationCurrent official DailyMed label, updated June 18, 2026, current archive June 30, 2026; indications, relevant safety sections 5.2, 5.3, 5.5, 5.6, 5.10, postmarketing experience and oral-drug interaction sections reviewed. Other sections not fully reviewed. · Checked 2026-10-21
- DailyMed: ZEPBOUND tirzepatide current prescribing informationCurrent official DailyMed label, updated August 28, 2026, current archive September 2, 2026; indications, relevant safety sections 5.2 through 5.5 and 5.9, postmarketing experience and oral-drug interaction sections reviewed. Other sections not fully reviewed. · Checked 2026-10-21